Abstract: This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided.

Abstract: The present invention provides a biomarker PCDH9 for molecular classification of prostate cancer and for evaluation of prostate cancer prognosis and uses thereof. The biomarker PCDH9 can be DNA or mRNA of PCDH9 or a protein encoded thereby. The present invention also provides a prostate cancer in vitro diagnostic product comprising a detection reagent of the biomarker PCDH9.

Abstract: The present invention provides an application of PLXNA1 as a biomarker for predicting the occurrence, development, and prognosis of prostate cancer and for distinguishing prostate cancer being progressive and with high malignancy. By detecting a change in a PLXNA1 DNA copy number, and expression levels of mRNA and a protein encoded thereby, a diagnosis and prognosis of prostate cancer are performed. The present invention also provides an application of PLXNA1 as a therapeutic target for prostate cancer. The present invention also provides a kit for diagnosing and predicting prostate cancer.